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Angiogenesis, the development of new blood vessels from 
quiescent endothelium, is an inevitable process in a variety of
physiological conditions including wound healing, embryonic
development and organ regeneration. Conversely, persistent
uncontrolled angiogenesis are known to contribute to the progres-
sion of many human diseases such as tumour, diabetic retinopathy
and rheumatoid arthritis (Folkman, 1985). In particular, the expan-
sion of solid tumours beyond 2–3 mm in size is critically depen-
dent on the formation of new blood vessels of supply nutrients and
oxygen (Hanahan and Folkman, 1996). The process of angio-
genesis is complex and involves several discrete events, such as
proliferation and migration of endothelial cells, and extracellular
matrix (ECM) degradation. Up to date, a wide variety of growth
factors and cytokines have been identified as positive or negative
regulators of angiogenesis.
Insulin-like growth factor (IGF)-II, a polypeptide which has
structural homology with insulin and IGF-I, is known to play a
role in regulating proliferation and differentiation in a variety of
cell types (Cohick and Clemmons, 1993). In fetal development,
IGF-II was recognized as a crucial fetal growth factor, as was iden-
tified in high concentrations in multiple fetal tissues (Bowsher et
al, 1991) and the disruption of IGF-II gene in mice resulted in
substantial growth retardation (DeChiara et al, 1990). IGF-II also
stimulated the differentiation of neuronal and muscle cells. The
effects of IGF-II on cells were exerted by its interaction with three
major cell surface receptors: the insulin receptor, the type-I IGF
receptor (IGF-IR), and type-II IGF receptor (IGF-IIR) and the
activity of IGF-II is also modulated by specific IGF binding
proteins. IGF-II binds with high affinity to the IGF-IIR even
though IGF-II binds with lower affinity to the insulin receptors and
the IGF-IR. Two latter receptors are structurally similar and have
an intrinsic tyrosine kinase activity. The mitogenic activity of IGF-
II is generally considered to be mediated by an interaction with
IGF-IR (Storchenfeldt et al, 1991). IGF-IIR is distinct from two
other IGF receptors, and possesses a short cytosolic tail that lacks
an intrinsic tyrosine kinase activity (Stewart and Rotwein, 1996).
Concerning with the intracellular signalling pathways transferred
by IGF-IIR is not clearly identified. However, several lines of
evidence have been reported that IGF-IIR may be coupled to G
protein (Nishimoto, 1993). Recently, Groskopf et al (1997)
demonstrated in bovine capillary endothelial cells that proliferin-
induced chemotaxis mediated by an interaction of this hormone
with IGF-IIR occurs through a G protein coupled pathway, and
that the chemotactic response requires the MAPK activation.
The involvement of IGF-II has been implicated in the growth
regulation of human tumours (Daughaday, 1990). Many
researchers have observed independently that IGF-II was highly
expressed in a number of human tumours, which include Wilms’
tumour (Reeve et al, 1985), breast tumour (Cullen et al, 1991),
neuroblastoma (Sullivan et al, 1995) and rhabdomyosarcoma
(Minniti et al, 1994). In addition, IGF-II is known to stimulate the
growth of hepatocellular carcinoma (HCC) cells in vitro (Kraft et
al, 1993). We also found previously that most cirrhotic and HCC
tissues express IGF-II, and in a subsequent study we demonstrated
that IGF-II secreted from HCC functions as an angiogenic factor
directly as well as indirectly through increase in vascular endothe-
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Summary Insulin-like growth factor II (IGF-II), highly expressed in a number of human tumours, has been recently known to promote
neovascularization in vivo. Yet, the detailed mechanism by which IGF-II induces angiogenesis has not been well defined. In the present study,
we explored an angiogenic activity of IGF-II in in vitro angiogenesis model. Human umbilical vein endothelial cells (HUVECs) treated with
IGF-II rapidly aligned and formed a capillary-like network on Matrigel. In chemotaxis assay, IGF-II remarkably increased migration of
HUVECs. A rapid and transient activation of p38 mitogen-activated protein kinase (p38 MAPK) and p125 focal adhesion kinase (p125FAK)
phosphorylation was detected in HUVECs exposed to IGF-II. IGF-II also stimulated invasion of HUVECs through a polycarbonate filter coated
with Matrigel. Quantitative gelatin-based zymography identified that matrix metalloproteinase-2 (MMP-2) activity generated from HUVECs
was increased by IGF-II. This induction of MMP-2 activity was correlated with Northern blot analysis, showing in HUVECs that IGF-II
increased the expression of MMP-2 mRNA, while it did not affect that of TIMP-2, a tissue inhibitor of MMP-2. These results provide the
evidence that IGF-II directly induces angiogenesis by stimulating migration and morphological differentiation of endothelial cells, and suggest
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Correspondence to: KW Kimlial growth factor (VEGF) production (Kim et al, 1998). The direct
angiogenic activity of IGF-II in rat cornea was also observed by
Volpert et al (1996). Therefore, the importance of IGF-II as an
angiogenic factor has been emphasized. However, the specific
molecular function of IGF-II in promoting angiogenesis remains
to be further investigated.
In the present study, the mechanisms of IGF-II in the regulation
of angiogenesis were studied in HUVECs. We demonstrate that
IGF-II induces angiogenesis by directly stimulating endothelial
cell migration and tube formation. In addition, IGF-II stimulates
invasiveness of HUVECs into the basement membrane (BM)
through up-regulation of the expression of proteolytic enzyme,
MMP-2.
MATERIALS AND METHODS
Cell culture
HUVECs were obtained from the American Type Culture
Collection. The cells were maintained in a gelatin-coated 75-cm2
flask in M199 (Life Technologies) supplemented with 20% fetal
bovine serum (FBS), 100 units ml–1 penicillin, 100 mg ml–1 strepto-
mycin, 3 ng ml–1 basic fibroblast growth factor (bFGF) (Life
Technologies), and 5 units ml–1 heparin (Life Technologies) at
37°C under 5% carbon dioxide, 95% air. IGF-II was purchased
from R&D Systems Inc.
[3H]Thymidine incorporation assay
HUVECs were seeded at a density of 1 ´ 104 cells per well in
24-well plate. Cells were incubated in growth media and allowed
to attach for 24 h. Cells were washed two times with M199 and
incubated for 12 h in M199 containing 1% FBS. Cells were stimu-
lated by the addition of the indicated concentration of IGF-II or
10 ng ml–1 of bFGF for 4 days, followed by the addition of 
1 mCi ml–1 [3H]thymidine for 5 h. High molecular mass [3H]-
radioactivity was precipitated using 5% trichloroacetic acid at 4°C
for 30 min. After two washes with ice-cold water, [3H]-radio-
activity was solubilized in 0.2 N sodium hydroxide and 0.1%
sodium dodecyl sulphate (SDS), and determined by liquid scintil-
lation counter.
Growth of HUVECs on Matrigel
A total of 250 ml of Matrigel (Collaborative Research) was
pipetted into a 16 mm diameter tissue culture wells and polymer-
ized for 30 min at 37°C (Albini et al, 1995). HUVECs were
harvested with trypsin, resuspended in M199 with 10% FBS,
plated onto a layer of Matrigel at a density of 4 ´ 105 cells per well,
and followed by the addition of bFGF (30 ng ml–1) and heparin (30
mg ml–1) or IGF-II (100 ng ml–1). Matrigel cultures were incubated
at 37°C, After 24 h, the cultures were photographed.
Chemotaxis assay
The chemotatic motility of HUVECs was determined by a modi-
fied Boyden chamber assay. Briefly, the lower surface of the
polycarbonate filter (12 mm pore, Millipore) was coated with
10 ml of 0.5 mg ml–1 type I collagen. IGF-II or bFGF, prepared in
600 ml of M199 with 1% FBS, was placed in the lower wells.
HUVECs were trypsinized and suspended at a final concentration
of 5 ´ 105 cells ml–1 in M199 containing 1% FBS. Then, 400 ml of
cell suspension was loaded into each of the upper wells. The
chamber was incubated at 37°C for 4 h. Cells were fixed and
stained with haematoxylin and eosin. Non-migrating cells on the
upper surface of the filter were removed by wiping with a cotton
swab, and chemotactic motility was quantified by counting the
cells that migrated to the lower side of the filter with optical
microscopy at ´400 magnification. Thirteen fields were counted
for each assay. Each sample was assayed in triplicate, and the
assays were repeated twice.
In vitro invasion assay
In vitro invasion assay was performed as described for chemotaxis
assay with exceptions that the upper side of filter was coated with
50 ml of 0.2 mg ml–1 Matrigel and incubation time was 7 h.
Immunoprecipitations
Confluent HUVECs were incubated for 24 h in M199 containing
1% FBS. The cells were treated with IGF-II or VEGF (Upstate
Biotechnology) for 10 min, lysed at 4°C in 1 ml of a lysis buffer
containing 10 mM Tris–HCl, pH 7.6, 5 mM EDTA, 50 mM sodium
chloride (NaCl), 50 mM b-giycerophosphate, 50 mM sodium
fluoride, 0.1 mM Na3Vo 4, 1 mM phenylmethylsulphonyl fluoride,
0.5% Nonidet P-40, and 1% Triton X-100. Lysates were clarified
by centrifugation at 15 000 g for 10 min and precleared by
incubation with protein A-agarose beads (Upstate Biotechnology)
for 1 h at 4°C. After removal of protein A-agarose by brief
centrifugation, the supernatants were transferred to fresh tubes for
immunoprecipitation. Immunoprecipitation was performed by
incubating lysates with 1 mg ml–1 of anti-p125FAK antibody
(Upstate Biotechnology) for 3 h at 4°C. Immunocomplexes were
collected by incubating lysates with protein A-agarose beads for a
further 1 h. Immunoprecipitates were washed three times with
lysis buffer and further analysed by Western blotting.
Western blotting
Cell lysates or immunoprecipitates from HUVECs were loaded
into a 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
gel, and transferred to polyvinyldifluoride membrane (Immobilon
P, Millipore Corp.). The blocked membranes were then incubated
with anti-phospho-specific p38 MAPK (New England Biolabs),
anti-p38 MAPK (Santa Cruz Biotechnology), anti-phosphotyro-
sine (PY20, Transduction Laboratories), or anti-p125FAK anti-
body (Upstate Biotechology), and the immunoreactive bands were
visualized using chemiluminescent reagent as recommended by
Amersham Pharmacia Biotechnolgy. The signals of the bands
were quantitated using a densitometer.
Gelatin zymography
HUVECs were seeded at a density of 2 ´ 106 cells per well of a
6-well plate. After 2 days, cells were rinsed with serum-free
medium twice, and then incubated in 3 ml of serum-free medium
with or without IGF-II for 12 h. The amount of secreted proteins in
the conditioned media was quantified by Bio-Rad protein assay
(Bio-Rad). The conditioned media containing 3 mg of secreted
proteins were analysed by gelatin-based zymography, using a
slightly modified procedure from that of Herron et al (1986). The
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co-polymerized with gelatin (0.33 mg ml–1). After electrophoresis,
the gel was rinsed twice with 2.5% Triton X-100 for 15 min and
incubated for 18 h at 37°C in incubation buffer (0.05 M Tris–HCl
(pH 7.5), 0.15 M NaCl, 0.01 M calcium chloride, 1 mM zinc chlo-
ride). Gelatinase was identified following staining of the gel in
0.25% Coomassie blue R250 and destaining in 7% acetic acid. The
digested area appeared clear on a blue background, indicating the
location of gelatinase.
Northern blot analysis
Total RNAs were prepared from HUVECs using the Tri Reagent
kit (Molecular Research Center). RNAs (30 mg) were electro-
phoresed on formaldehyde agarose gels, transferred to Zeta-Probe
membranes (Bio-Rad), and probed with 32P-labelled MMP-2,
TIMP-2, or b-actin cDNA fragments. The filter was prehybridized
at 42°C for 1 h with hybridization buffer containing 50% deion-
ized formamide, 7% SDS, 0.12 M NaHPO4 and 0.25 M NaCl and
then hybridized at 42°C overnight in hybridization buffer with
denatured labelled probes. After hybridization, the filter was
washed at 42°C in 2 ´ SSC (1 ´ SSC = 0.15 M NaCl and 0.015 M
sodium citrate), 0.1% SDS for 15 min and 0.5 ´ SSC, 0.1% SDS
for 15 min. The filter was then exposed to X-ray film. The signals
of the bands were quantitated using a densitometer.
Statistical analysis
Results are expressed as mean ± s.e.m. or as percentage ± s.e.m. of
control. Statistical comparisons between groups were performed
using the Student’s t-test.
RESULTS
IGF-II induces vascular tube formation on Matrigel
Previously, we have demonstrated that IGF-II has a direct angio-
genic activity in chick chorioallantoic membrane (CAM) assay
(Kim et al, 1998). However, the detailed mechanisms involved in
the regulation of angiogenesis by IGF-II have not been clearly
identified. To analyse the direct angiogenic activities of IGF-II on
endothelial cells, we have first examined the effect of IGF-II on
proliferation of HUVECs by [3H]thymidine incorporation assay.
IGF-II did not affect the proliferation of HUVECs at the concen-
tration of ranges from 10 ng ml–1 to 100 ng ml–1 while HUVEC
proliferation was strongly stimulated by 10 ng ml–1 bFGF (Figure
1). Higher concentration of IGF-II up to 1 mg ml–1 had no effect on
the proliferation of HUVECs (data not shown). Next, we examined
the effect of IGF-II on the morphological differentiation of
HUVECs on Matrigel. HUVECs resuspended in M199 containing
10% FBS without any other supplements were seeded at high
density (4 ´ 105 cells) on plates coated with Matrigel. In this 
condition, HUVECs did not form complete network within 24 h
(Figure 2A) and as usual it takes 3 days to form an organized 
tube-like structure. However, HUVECs stimulated with IGF-II
(100 ng ml–1) rapidly aligned and formed an anastomosing capil-
lary-like network, and complete networks were observed after 24 h
(Figure 2C). Thus, the effect of IGF-II on the morphology of
HUVECs on Matrigel was similar to that of bFGF (Figure 2B).
The rapid formation of tube network by IGF-II suggests that IGF-
II may increase the migratory and invasive activities of HUVECs.
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Figure 1 The effect of IGF-II on DNA synthesis of HUVECs. IGF-II (10, 50,
or 100 ng ml–1) was added to HUVECs and incubated for 4 days.
[3H]Thymidine was present during the last 5 h of incubation. bFGF 
(10 ng ml–1) was used as a positive control. The data represent the 
means ± s.e.m. of triplicate, and similar results were obtained in at least two
different experiments. P < 0.001 from control
A
B
C
Figure 2 IGF-II induces tube formation of HUVECs on Matrigel. HUVECs
were plated on Matrigel-coated wells as described in Materials and Methods.
Cultures were photographed after 24 h of incubation in the absence of
activator (A), in the presence of 30 ng ml–1 of bFGF and 30 mg ml–1 of heparin
(B), or in the presence of 100 ng ml–1 of IGF-II (C) (´40)IGF-II induces HUVEC migration
To further investigate the mechanism associated with IGF-II-
stimulated tube formation, we examined the effect of IGF-II on
HUVEC migration using a modified Boyden chamber assay. As
shown in Figure 3, IGF-II stimulated the chemotactic motility of
HUVECs in a dose-dependent manner and the migratory activity
at 100 ng ml–1 of IGF-II was 60% increase over the control.
However, the stimulatory effect of IGF-II on chemotactic motility
of HUVECs was slightly weaker than that of bFGF (30 ng ml–1).
IGF-II induces p38 MAPK activation and p125FAK
phosphorylation
Recently, it has been reported that the p38 MAPK activity medi-
ates actin reorganization and cell migration whereas activation of
extracellular signal-regulated protein kinases (ERKs) is associated
with cell proliferation in HUVECs (Rousseau et al, 1997). Thus,
we postulated the possibility that IGF-II may stimulate endothelial
cell migration through p38 MAPK activation. To assess the effect
of IGF-II on p38 MAPK, we exposed confluent HUVECs to
various concentrations of IGF-II and measured the activation of
p38 MAPK with rabbit polyclonal phospho-specific anti-p38
MAPK, which only detects phosphorylated and activated form.
The specificity of phospho-specific anti-p38 MAPK was 
determined by bFGF (10 ng ml–1, for 10 min) and VEGF (5 or 10
ng ml–1, for 10 min) which are known stimuli of p38 MAPK in
HUVECs. As shown in Figure 4A, cells treated with either bFGF
or VEGF significantly increased the signals from immunoblot,
indicating that this antibody is specific to phosphorylated form of
p38 MAPK. The activation of p38 MAPK by IGF-II was evident
at 10 ng ml–1 and gradually increased in a dose-dependent manner
(Figure 4B). In contrast, IGF-II even at 300 ng ml–1 did not affect
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Figure 3 IGF-II induces chemotactic migration of HUVECs. HUVECs were
plated on polycarbonate filter of the upper compartment and exposed for 4 h
to 30 ng ml–1 bFGF or the indicated concentration of IGF-II added to the
lower compartment. The detailed experimental procedures are described in
Materials and Methods. Results are expressed as percentage ± s.e.m. of
control. Each sample was assayed in triplicate, and the assays were
repeated twice. P < 0.001 from control
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Figure 4 IGF-II induces activation of p38 MAPK in HUVECs. (A) Effect of bFGF or VEGF on activation of p38 MAPK. Confluent HUVECs were stimulated for
10 min with or without bFGF (10 ng ml–1) and VEGF (5 or 10 ng ml–1). (B) Dose-dependent p38 MAPK activation. HUVECs were stimulated with various
concentrations of IGF-II for 10 min. (C) Time courses of IGF-II-induced p38 MAPK activation. HUVECs were stimulated with 100 ng ml–1 of IGF-II for the
indicated times. p38 MAPK activation was determined by Western blot analysis using anti-phospho-specific p38 MAPK antibody (P-p38), which only detects
phosphorylated and activated from of p38 MAPK. The amount of proteins was checked by reprobing the membrane with antibody to p38 MAPK (p38). The
graphs represented quantitative results from densitometeric analysis. Values shown are the mean ± s.e.m. of three independent experiments and are expressed
as fold-stimulation above control. *P < 0.005; ** P < 0.001 from controlphosphorylation of ERK1/2 that was, however, strongly activated
by bFGF and VEGF (data not shown). This is well consistent with
our observation that IGF-II has no effect on HUVEC proliferation.
The activity of p38 MAPK was determined in HUVECs exposed
to 100 ng ml–1 of IGF-II at various periods of time. IGF-II induced
a rapid activation of p38 MAPK that reached a peak of fourfold
over basal level and maintained until 10 min (Figure 4C).
We have next investigated whether IGF-II activated p125FAK
whose activation is correlated with cell adhesion and migration.
Confluent HUVECs were treated with 100 ng ml–1 of IGF-II for 
10 min and anti-p125FAK immunoprecipitates were prepared and
blotted by anti-phosphotyrosine antibody. IGF-II stimulated tyrosine
phosphorylation of p125FAK by twofold over the control (Figure 5).
The effect of IGF-II was similar to that of VEGF (10 ng ml–1).
IGF-II induces HUVECs to degrade and traverse the BM
through the regulation of expression of MMP-2
To form new blood vessels, the migrating endothelial cells must
break and traverse their own BM (Sage, 1997). To study the ability
of IGF-II to stimulate invasion, we coated the polycarbonate filter
with Matrigel preventing the migration of noninvasive cells
(Albini et al, 1987). HUVECs were seeded on the filter and
allowed to invade: bFGF (50 ng ml–1) stimulated strongly the 
invasion of HUVECs. As similar to bFGF, IGF-II significantly
promoted the invasion of HUVECs at the concentration of ranges
from 10 ng ml–1 to 100 ng ml–1 (Figure 6). An essential pattern of
this invasion includes degradation of the BM. MMPs are a family
of inducible enzymes that degrade ECM components, allowing
cells to traverse BM efficiently. Therefore, we performed gelatin
zymography to examine the effect of IGF-II on the expression of
MMP-1, 2, 3 and 9. Analysis of serum-free conditioned medium of
non-stimulated HUVECs showed the presence of gelatinolytic
activity at 72 kDa MMP-2. IGF-II increased the expression of
MMP-2 by 2.5-fold at a concentration of 100 ng ml–1, but it had no
effect on the expression of MMP-1, 3 and 9 (Figure 7). We used
the conditioned medium of phorbol 12-myristate 13-acetate
(PMA)-stimulated HUVECs for distinguishing the type of MMPs
(Hanemaaijer et al, 1993). PMA at a concentration of 40 ng ml–1
induced several MMPs including MMP-9 (92 kDa), active form of
MMP-2 (64 kDa) and MMP-1/MMP-3 (55 kDa).
To confirm the induction of MMP-2 by IGF-II, we conducted
Northern blot analysis using specific cDNA probes for MMP-2
and its inhibitor, TIMP-2. IGF-II (100 ng ml–1 for 12 h) induced a
threefold increase in the expression of MMP-2 mRNA (Figure
8A). However, IGF-II had no significant effect on the expression
of TIMP-2 mRNA in HUVECs (Figure 8B). These results suggest
that the invasion activity of HUVECs by IGF-II may involve the
changed ratio of the levels of MMP-2 and TIMP-2.
DISCUSSION
High levels of IGF-II are found in a number of human tumours
including human HCC (Kim et al, 1998), Wilms’ tumour (Reeve 
et al, 1985), breast tumour (Cullen et al, 1991), neuroblastoma
(Sullivan et al, 1995) and rhabdomyosarcoma (Minniti et al,
1994). In these tumours, IGF-II is known to contribute to the
tumour growth. Previously, we reported that IGF-II, expressed in
nearly all of the cases of cirrhotic and HCC tissues, plays an
important role in the development of neovascularization of HCC.
IGF-II indirectly induced angiogenesis during HCC by increasing
the expression of VEGF in HCC cells and directly stimulated
angiogenesis in the CAM (Kim et al, 1998). In the present study,
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Figure 5 IGF-II stimulates p125FAK tyrosine phosphorylation in HUVECs.
Confluent cultures of HUVECs were treated with 10 ng ml–1 VEGF (A) or
100 ng ml–1 IGF-II (B) for 10 min. All cells used were lysed, and anti-p125FAK
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Figure 6 IGF-II stimulates invasion of HUVECs. HUVECs were treated with
the indicated concentrations of IGF-II. The cells invaded into BM and
migrated to the lower side of the filter were counted. A total of 50 ng ml–1
bFGF was used as a positive control. Results are expressed as percentages
of control ± s.e.m. *P < 0.05; ** P < 0.001 from control
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Figure 7 Gelatin zymography of the culture medium of HUVECs treated
with IGF-II. After treatment with 50 or 100 ng ml–1 of IGF-II for 12 h, the
culture media were used in gelatin-based electrophoresis and stained with
Coomassie brilliant blue. The culture medium from HUVECs treated with
PMA (40 ng ml–1 for 12 h) was used for distinguishing the types of MMPs
(lane 1)we have further demonstrated that IGF-II promotes the morpho-
logical differentiation of HUVECs into capillary-like structures on
Matrigel. This phenomenon is supported by the findings that
IGF-II remarkably increases cell migration and invasiveness.
Moreover, the mechanisms of these processes have been further
elucidated that IGF-II rapidly induced the activation of p38
MAPK and p125FAK phosphorylation, which may be involved in
the signalling pathways of regulating endothelial cell migration,
and substantially increased the expression of MMP-2, a major
ECM degrading enzyme expressed in HUVECs.
The overall mechanism of completing angiogenesis in vivo
requires an integral activation of endothelial cells, which includes
proliferation, migration, matrix invasion and tube formation
(Sage, 1997). IGF-II seemed not to be an endothelial cell mitogen
since it did not significantly stimulate DNA synthesis in at least
two types of endothelial cells, HUVECs in this study (Figure 1)
and bovine aortic endothelial cells by others (Bar et al, 1988).
In contrast to the lack of IGF-II activity in endothelial cell
proliferation, IGF-II strongly stimulated the capillary-like tube
formation of HUVECs on plates coated with Matrigel, which is a
reconstituted basement membrane (Figure 2). Endothelial cells
cultured on Matrigel can slowly form tubular network without any
other supplements because Matrigel has minimal amount of angio-
genic components such as laminin and bFGF. When high density
(~80%) of HUVECs were seeded on Matrigel, incomplete network
was formed within 24 h without any other supplements. However,
HUVECs treated with IGF-II rapidly moved, aligned and formed a
complete network within 24 h, with similar kinetics to that of 10
ng ml–1 bFGF. Thus, it is most likely that the direct angiogenic
activity of IGF-II previously observed in the quantitative CAM
assay (Kim et al, 1998) may be conferred by the stimulatory
activity on endothelial cell migration and differentiation rather
than proliferation.
Indeed, we observed that IGF-II markedly stimulated the migra-
tion of HUVECs as might have been expected (Figure 3).
Similarly, Volpert et al (1996) demonstrated that the placental
angiogenic hormone proliferin stimulates bovine capillary
endothelial cells (BCECs) migration in vitro and neovasculariza-
tion in the rat cornea by an interaction of this hormone with cell
surface IGF-IIR and IGF-II also induces BCEC migration through
its interaction with IGF-IIR rather than IGF-IR. In a subsequent
study, Groskopf et al (1997) suggested that chemotaxis initiated by
either proliferin or IGF-II binding to IGF-IIR occurs through a G
protein-coupled signalling pathway leading to the ERK activation.
In this study, we show that IGF-II noticeably induces the biphasic
activation of p38 MAPK with respect to time of treatment with
IGF-II in HUVECs (Figure 4) and also 100 ng ml–1 of IGF-II 
stimulated the tyrosine phosphorylation of p125FAK with similar
potency to that by 10 ng ml–1 of VEGF (Figure 5). The involve-
ment of MAPK pathways in cell migration was recently identified
(Rousseau et al, 1997). In HUVECs, the treatment of VEGF
induced actin reorganization, the formation of focal adhesion, and
cell migration, and those were inhibited by pretreatment with the
specific inhibitor of p38 MAPK, SB203580, but inhibiting the
VEGF-induced activation of ERK with PD098059 had no effect.
Furthermore, it has been suggested that VEGF-induced p125FAK
phosphorylation occurs through a pathway independent of ERK
activation (Abedi and Zachary, 1997). It is noteworthy that there
was a discrepancy in requirement of ERK pathway between
VEGF-induced HUVECs migration and IGF-II-induced BCEC
migration. This may be due to the differences in either cell types or
stimuli. On the basis of our observations, it would be predicted the
possibility that the molecular mechanism by which IGF-II stimu-
lates the migration of HUVECs may partly involve the formation
of focal adhesion mediated by p38 MAPK activation and p125FAK
phosphorylation, similar to VEGF-induced focal adhesion forma-
tion. However, much more remained to be investigated for the
roles of p38 MAPK and other signalling molecules leading to
HUVEC migration by IGF-II.
IGF-II-induced tube formation ability of HUVECs involves the
increase of invasiveness into the BM (Figure 6). The present data
demonstrated that IGF-II treatment increases the ability of
HUVECs to invade BM. An essential pattern of this process
includes degradation of the BM. Many proteolytic enzymes
secreted from endothelial cells during the progression of angio-
genesis have been reported to degrade components of the ECM
and BM. These proteolytic enzymes include MMP-1 (collagenase-
1), MMP-2 (gelatinase A; 72 kDa type IV collagenase), MMP-3
(stromelysin 1) and MMP-9 (gelatinase B; 92 kDa type IV colla-
genase) and can degrade native collagens, gelatin and other ECM
components. Interstitial collagens (type I, II and III), present in the
ECM, are degraded in a two-step process involving an initial
cleavage by MMP-1, followed by further degradation by MMP-2,
MMP-3 or MMP-9 (Matrisian, 1992). MMP-1, 2, 3, and 9 are
known to be expressed in HUVECs (Hanemaaijer et al, 1993).
Quiescent HUVECs showed an intrinsic MMP-2 activity and
weak activities of MMP-1/3. In gelatin-based zymography, a Mr 72
000 band of gelatinolysis, which is assigned to MMP-2 activity,
was noticeably increased in the conditioned media from HUVECs
treated with IGF-II compared to the control media (Figure 7). This
result suggested that IGF-II might up-regulate the expression of
MMP-2 protein. To confirm the increase in MMP-2 activity by
IGF-II, we have investigated the mRNA expression of MMP-2 and
TIMP-2, a tissue inhibitor of MMP-2. TIMP-2 is known to form
1:1 complexes with MMP-2 and that regulates the enzymatic
activity of MMP-2. Northern blot analysis (Figure 8) revealed that
treatment of HUVECs with IGF-II markedly up-regulated the
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Figure 8 Expression of MMP-2 and TIMP-2 in HUVECs treated with IGF-II.
A total of 30 mg of total RNA isolated from HUVECs treated with 50 or 
100 ng ml–1 of IGF-II for 12 h were analysed by Northern blot. The blots were
hybridized with 32P-labelled cDNA probes of MMP-2 (A) and TIMP-2 (B). To
assess loading differences, radiolabelled DNA was stripped from blot and
filters were reprobed with b-actin probemRNA expression of MMP-2, but not significantly TIMP-2. These
results are inconsistent with gelatin zymography analysis and indi-
cated that the increase in MMP-2 activity by IGF-II was due to the
increased expression of MMP-2. Thus, it is suggested that the
stimulatory effect of IGF-II on HUVEC invasion into BM can be
partly attributable to a breakdown of net proteolytic balance, at
least involving up-regulation of MMP-2 activity. The signalling
pathways through which IGF-II elicits the expression of MMP-2
gene remain to be unidentified. Further experimental work is
necessary to examine the correlation between activation of p38
MAPK and MMP-2 expression by IGF-II in HUVECs.
In summary, we have demonstrated that IGF-II directly induces
angiogenesis by stimulating cell migration, invasion and tube
formation. These results together with our previous observations
confer further evidence that the high level of IGF-II expression in
tumour may play a crucial role in the progression of tumorigenesis
by promoting the deleterious neovascularization.
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